Explainer · US

NAC supplements: FDA proposes letting them be sold lawfully

FDA has proposed a rule that would let products containing N-acetyl-L-cysteine (NAC) be lawfully marketed as dietary supplements if they are not otherwise in violation of the law, the first use of its rulemaking authority to lift the drug-first exclusion. What changes, what FDA's safety review found and what it does not mean.

Review type: research summary. This page summarises published research and product labels, cited below.

On November 16, 2026, the Food and Drug Administration (FDA) filed a proposed rule for public inspection that would allow products containing N-acetyl-L-cysteine (NAC) to be lawfully marketed as dietary supplements in the US if they are not otherwise in violation of the law. The rule is scheduled for publication in the Federal Register on November 17, 2026. FDA says this proposed rule is the first use of its rulemaking authority described in section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act, which is how an ingredient approved as a drug first can be allowed in supplements. NAC would be the first ingredient on a new list at 21 CFR 190.1.

Short answer: nothing changes on the shelf yet. Products labeled as NAC supplements are already sold. Since August 2022, FDA has said it intends to exercise enforcement discretion for those that would be lawful dietary supplements if NAC were not excluded and that are not otherwise in violation of the law. This proposal would end that legal gray zone if it is finalized. It is a decision about legal status, safety and whether supplement sales would impede drug development. It is not a finding that NAC improves health. In its economic analysis, FDA said it does not estimate benefits due to the proposed rule.

What NAC is

FDA describes NAC as a dietary ingredient: a dietary substance used to supplement the diet by increasing total dietary intake. As an approved drug, acetylcysteine has two uses that FDA describes in the proposal: to prevent or lessen liver injury after ingestion of a potentially liver-toxic amount of acetaminophen, and as an add-on treatment for patients with abnormal, thick, or dried mucus secretions in conditions such as chronic bronchopulmonary disease. NAC supplements are taken by mouth. NAC is also combined with glycine as "GlyNAC", covered in a separate article on this site.

Why NAC was stuck

Under the 1994 law that defined dietary supplements, an ingredient approved as a new drug before it was marketed as a supplement or as a food is excluded from the supplement definition. NAC was approved as a drug on September 14, 1963, under the brand name Mucomyst. The first-known NAC supplement advertisement FDA cites is from August/September 1991, so NAC fell on the wrong side of that line. FDA says it is not aware of any evidence that NAC was marketed as a dietary supplement or as a food before September 14, 1963, and it has asked for evidence to the contrary.

  • 2001 and 2010: FDA stated in a response to a health claim petition, and later in a letter about an NAC ethyl ester ingredient, that NAC products could not be dietary supplements.
  • July 2020: FDA warning letters to companies selling hangover products labeled as dietary supplements said that NAC products are excluded from the supplement definition. One letter to Hangover Heaven also said that claims to prevent hangovers made its product an unapproved new drug.
  • 2021: two trade groups, the Council for Responsible Nutrition and the Natural Products Association, petitioned FDA to reverse its position, and the Natural Products Association also asked, as an alternative, for a rule allowing NAC in supplements.
  • March 31, 2022: FDA denied the request to change its legal conclusion, but said it was still considering the rulemaking request.
  • August 2022: FDA's final guidance said it intends to exercise enforcement discretion for NAC products labeled as dietary supplements that would be lawful if NAC were not excluded and that are not otherwise in violation of the law.

What the proposed rule would do

The rule would create 21 CFR 190.1, "Dietary ingredients not excluded from the dietary supplement definition", and list N-acetyl-L-cysteine as its only ingredient, with room to add others later. It would also provide that adding NAC to a dietary supplement is not a prohibited act under section 301(ll), the provision that otherwise makes it a prohibited act to add an approved drug, or certain biologics, to a food. NAC products would then have to meet all the normal rules for supplements, including current good manufacturing practice under 21 CFR part 111. FDA notes that any adulterated or misbranded product may still face enforcement action.

FDA proposes that the final rule take effect immediately on publication, because it relieves a restriction, and asks for comment on that timing. If the rule is finalized, FDA intends to withdraw the 2022 enforcement discretion guidance. Comments are due 60 days after publication and can be filed electronically at Regulations.gov under docket FDA-2025-N-2699.

Why FDA says it is safe enough

FDA says Congress limited this authority to two conditions: regulating the ingredient as a supplement would provide adequate safeguards, and allowing it would be unlikely to impede new drug development. On safety, FDA says its drug approvals of NAC do not settle the question, because a drug review weighs risks against benefits, while a supplement assessment generally considers only risk. It ran a systematic review of studies of NAC taken by mouth, with a protocol, results analysis and conclusions that underwent external peer review.

  • 41 studies were rated high confidence and used for conclusions.
  • Doses ranged from 200 mg to 9,000 mg a day, for 5 days to 3 years, in groups ranging from healthy people to patients with end-stage kidney disease.
  • One study found a significant increase in nausea with NAC. Most others reported no adverse events, or adverse events not significantly different from comparison groups.
  • The commonly reported adverse events were gastrointestinal pain or discomfort, nausea, vomiting, and rash. FDA describes the gastrointestinal symptoms as non-serious.
  • Products labeled as NAC supplements most often list a serving of 600 mg, 1,000 mg, or 1,200 mg a day, which FDA says overlaps with the doses studied, including multiple studies at 1,200 mg a day.

FDA concluded a "minimal" level of concern and a reasonable expectation of safety for NAC in supplements. Two points of scope matter. The review looked at adverse events, not at whether NAC does anything useful. FDA advises consumers to talk with a doctor, pharmacist, or other healthcare professional before using a dietary supplement.

Why FDA says drug development will not suffer

The original Mucomyst application was withdrawn in 2009 at the sponsor's request, for reasons FDA says were not about safety or effectiveness. Acetylcysteine remains an approved drug: an injectable version, Acetadote, was approved on January 23, 2004, and FDA counts 19 current generic applications. FDA also found 832 clinical trials of NAC as a drug. Because NAC supplements have been sold alongside approved NAC drugs since at least 1991 without, in FDA's view, harming that research, it concludes that removing the exclusion is unlikely to hurt drug development. It says it has received no comments showing otherwise and invites them now.

The cost estimate is small. FDA says few firms operate in the NAC market, and it estimates the cost as the time for industry to read and understand the rule, with a present value of about $848 in total.

What it does not change

  • It is not an approval. FDA does not approve dietary supplements before they are sold to the public.
  • Disease claims stay off limits. A supplement cannot be sold to cure, treat, mitigate or prevent a disease; in a 2020 warning letter, FDA said hangover-prevention claims made one NAC product an unapproved new drug.
  • Approved acetylcysteine drugs stay separate, with the uses FDA has already approved.

Our view

  • This is good news for legal clarity: NAC supplements have sat in a gray zone for decades, and the proposal would put them on the same footing as other supplements, with the same manufacturing rules.
  • FDA's safety case is reasonably strong for an ingredient of this kind: 41 high-confidence studies, study doses up to 9,000 mg a day, and commonly reported effects that FDA describes as non-serious gastrointestinal symptoms, plus rash.
  • The rule does not estimate benefits, and its safety review looks at adverse events rather than whether NAC helps. Claims about NAC for liver health, lungs, mood, or aging need their own evidence.
  • Until a final rule is published, the 2022 enforcement discretion policy remains the basis on which NAC supplements are sold.
  • FDA advises talking with a doctor, pharmacist, or other healthcare professional before using a dietary supplement. If you think a supplement may have caused a serious reaction or illness, immediately stop using it and report it through FDA's Safety Reporting Portal.

FAQ

Can I still buy NAC supplements?

Yes. Since August 2022, FDA has said it intends to exercise enforcement discretion for NAC products labeled as dietary supplements that would be lawful if NAC were not excluded and that are not otherwise in violation of the law. The proposed rule, if finalized, would remove that exclusion. FDA says it would then withdraw the 2022 policy.

When would the rule take effect?

Not yet. Comments are due 60 days after publication in the Federal Register, scheduled for November 17, 2026. FDA would review timely comments before any final rule, which it proposes would take effect immediately on publication.

Does this mean NAC works?

No. The rule is based on a safety review of adverse events and on the effect on drug development. FDA said it does not estimate benefits due to the proposed rule, and nothing in the rule authorizes a claim to treat, cure, mitigate, or prevent disease.

How do I report a side effect from a supplement?

FDA asks consumers who think a dietary supplement caused a serious reaction or illness to stop using the product and file a report through the Safety Reporting Portal.

Sources

These are the documents this page relies on.

  1. Rulemaking to Provide That N-acetyl-L-cysteine Is Not Excluded from the Dietary Supplement Definition. Proposed rule, 21 CFR Part 190, Docket No. FDA-2025-N-2699, FR Doc. 2026-23351 (filed for public inspection November 16, 2026; scheduled for publication November 17, 2026)Food and Drug Administration, Federal Register
  2. Docket FDA-2025-N-2699: comments on the proposed rule on N-acetyl-L-cysteineRegulations.gov
  3. Guidance for Industry: Policy Regarding N-acetyl-L-cysteine (August 2022)US Food and Drug Administration
  4. FDA Issues Response to Two Citizen Petitions on NAC in Dietary Supplements (constituent update, March 31, 2022, with August 2022 final guidance update)US Food and Drug Administration
  5. Warning letter to Vita Heaven, LLC dba Hangover Heaven, July 23, 2020US Food and Drug Administration
  6. How to Report a Problem with Dietary SupplementsUS Food and Drug Administration
  7. Information for consumers on using dietary supplementsUS Food and Drug Administration